Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Investors Lab
  • Published:

More than meets the eyes?

Nature Biotechnology volume 22, page 1221 (2004)Cite this article

Access through your institution
Buy or subscribe

The competition to treat macular degeneration offers biotech investors an exciting story and great investing tips. Where everyone looks, company valuations are usually too rich to allow enough potential return for the risk. But where others avert their eyes, unpopularity may offer the opposite.

Huge unmet need

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. van Brunt, J. The eyes have it. Signals Magazine [online] http://www.signalsmag.com (May 2004).

    Google Scholar 

Download references

Authors
  1. Tom Jacobs
    View author publications

    Search author on:PubMed Google Scholar

Additional information

Tom Jacobs is cofounder of Complete Growth Investor (). He welcomes your comments at . Tom owns no shares of companies mentioned in this article.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, T. More than meets the eyes?. Nat Biotechnol 22, 1221 (2004). https://doi.org/10.1038/nbt1004-1221

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1004-1221

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing